Filing Details

Accession Number:
0001104659-22-057601
Form Type:
13G Filing
Publication Date:
2022-05-08 20:00:00
Filed By:
Partner Fund Management
Company:
Adaptimmune Therapeutics Plc (NASDAQ:ADAP)
Filing Date:
2022-05-09
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
PFM Health Sciences 0 54,658,680 0 5.8%
PFM Health Sciences GP 0 54,658,680 0 5.8%
Partner Asset Management 0 54,658,680 0 5.8%
Brian D. Grossman 0 54,658,680 0 5.8%
Filing

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
SCHEDULE 13G
(Rule 13d-102)
 
Information Statement Pursuant to Rules 13d-1 and 13d-2
Under the Securities Exchange Act of 1934
(Amendment No.       )*
 
 
  Adaptimmune Therapeutics PLC  
(Name of Issuer)
 
  Ordinary shares, in the form of American Depositary Shares**  
(Title of Class of Securities)
 
  00653A107  
  (CUSIP Number)  
     
  April 28, 2022  
  (Date of Event Which Requires Filing of the Statement)  

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨Rule 13d-1(b)
xRule 13d-1(c)
¨Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

** Each American Depository Share (“ADS”) represents 6 Ordinary Shares, par value £0.001 per share.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

 

CUSIP NO. 00653A107 13G Page 2 of 10 Pages

 

1. NAME OF REPORTING PERSON
   
  PFM Health Sciences, LP
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
  (a)       ¨
  (b)       x
3. SEC USE ONLY  
4. CITIZENSHIP OR PLACE OF ORGANIZATION
  Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5. SOLE VOTING POWER
  0
6. SHARED VOTING POWER
  54,658,680 ordinary shares1
7. SOLE DISPOSITIVE POWER
  0
8. SHARED DISPOSITIVE POWER
  See Row 6 above
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
  See Row 6 above  
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ 
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
  5.8%2  
     
12. TYPE OF REPORTING PERSON  
  IA; PN  

 

 

 

1Includes 54,685,680 Ordinary Shares of the issuer that are represented by 9,109,780 American Depositary Shares (“ADS”) directly held by the Funds. Each ADS represents 6 Ordinary Shares of the issuer.

 

2The percentages reported in this Schedule 13G are based upon 941,191,902 ordinary shares outstanding as of April 19, 2022 (according to the issuer’s definitive proxy statement filed with the Securities and Exchange Commission on April 21, 2022). All of the other numbers and percentages reported in this Schedule 13G are as of 9:00 a.m. (ET) on the date of filing.

 

 

 

 

CUSIP NO. 00653A107 13G Page 3 of 10 Pages

 

1. NAME OF REPORTING PERSON
   
  PFM Health Sciences GP, LLC
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
  (a)       ¨
  (b)       x
3. SEC USE ONLY  
4. CITIZENSHIP OR PLACE OF ORGANIZATION
  Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5. SOLE VOTING POWER
  0
6. SHARED VOTING POWER
  54,658,680 ordinary shares
7. SOLE DISPOSITIVE POWER
  0
8. SHARED DISPOSITIVE POWER
  See Row 6 above
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
  See Row 6 above  
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ 
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
  5.8%  
     
12. TYPE OF REPORTING PERSON  
  OO  

 

 

 

 

CUSIP NO. 00653A107 13G Page 4 of 10 Pages

 

1. NAME OF REPORTING PERSON
   
  Partner Asset Management, LLC
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
  (a)       ¨
  (b)       x
3. SEC USE ONLY  
4. CITIZENSHIP OR PLACE OF ORGANIZATION
  Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5. SOLE VOTING POWER
  0
6. SHARED VOTING POWER
  54,658,680 ordinary shares
7. SOLE DISPOSITIVE POWER
  0
8. SHARED DISPOSITIVE POWER
  See Row 6 above
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
  See Row 6 above  
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ 
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
  5.8%  
     
12. TYPE OF REPORTING PERSON  
  OO  

 

 

 

 

CUSIP NO. 00653A107 13G Page 5 of 10 Pages

 

1. NAME OF REPORTING PERSON
   
  Brian D. Grossman
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
  (a)       ¨
  (b)       x
3. SEC USE ONLY  
4. CITIZENSHIP OR PLACE OF ORGANIZATION
  U.S. Citizen
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5. SOLE VOTING POWER
  0
6. SHARED VOTING POWER
  54,658,680 ordinary shares
7. SOLE DISPOSITIVE POWER
  0
8. SHARED DISPOSITIVE POWER
  See Row 6 above
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
  See Row 6 above  
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨ 
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
  5.8%  
     
12. TYPE OF REPORTING PERSON  
  IN  

 

 

 

 

CUSIP NO. 00653A107 13G Page 6 of 10 Pages

 

Item 1(a)Name of Issuer
  
 Adaptimmune Therapeutics PLC

 

Item 1(b)Address of Issuer’s Principal Executive Offices
  
 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, United Kingdom, OX14 4RX

 

Item 2(a)Name of Person Filing
  
 This Schedule 13G is being jointly filed by PFM Health Sciences, LP (“PFM”), PFM Health Sciences GP, LLC (“PFM-GP”), Partner Asset Management, LLC (“PAM”), and Brian D. Grossman (“Grossman” and, collectively with PFM, PFM-GP, and PAM, the “Reporting Persons”) with respect to ordinary shares of the above-named issuer owned by PFM Healthcare Master Fund, L.P., a Cayman Islands limited partnership (“HCM”), and PFM Biotech Opportunities LP, a Delaware limited partnership (“BO” and, collectively with HCM, the “Funds”).

 

PFM is the investment advisor for the Funds. PAM is the general partner of the Funds. PFM-GP is the general partner of PFM and the manager of PAM. Grossman is the sole member of PFM-GP.

 

The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).

 

Item 2(b)Address of Principal Business Office
  
 The address of the principal business office of each of the Reporting Persons is c/o PFM Health Sciences, LP, 475 Sansome Street, Suite 1720, San Francisco, California 94111.

 

Item 2(c)Citizenship
  
 PFM is organized as a limited partnership under the laws of the State of Delaware. Each of PFM-GP and PAM is organized as a limited liability company under the laws of the State of Delaware. Grossman is a U.S. citizen.

 

Item 2(d)Title of Class of Securities
  
 Ordinary shares, par value £0.001 per share

 

Item 2(e)CUSIP Number
  
 00653A107

 

 

 

 

CUSIP NO. 00653A107 13G Page 7 of 10 Pages

 

Item 3If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

 

(a)¨ Broker or dealer registered under Section 15 of the Exchange Act;

 

(b)¨ Bank as defined in Section 3(a)(6) of the Exchange Act;

 

(c)¨ Insurance company as defined in Section 3(a)(19) of the Exchange Act;

 

(d)¨ Investment company registered under Section 8 of the Investment Company Act;

 

(e)¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

 

(f)¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

 

(g)¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

 

(h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

 

(i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

 

(j)¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

 

(k)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

 

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

 

 

 

 

CUSIP NO. 00653A107 13G Page 8 of 10 Pages

 

Item 4Ownership

 

A.PFM Health Sciences, LP, PFM Health Sciences GP, LLC and Partner Asset Management, LLC

 

(a)PFM, PFM-GP and PAM may be deemed to beneficially own 54,658,680 ordinary shares.

 

(b)The number of shares PFM, PFM-GP and PAM may be deemed to beneficially own constitutes approximately 5.8% of the ordinary shares outstanding.

 

(c)Number of shares as to which such person has:

 

(i)sole power to vote or to direct the vote: 0

 

(ii)shared power to vote or to direct the vote: 54,658,680

 

(iii)sole power to dispose or to direct the disposition of: 0

 

(iv)shared power to dispose or to direct the disposition of: 54,658,680

 

B.Brian D. Grossman

 

(a)Grossman may be deemed to beneficially own 54,658,680 ordinary shares.

 

(b)The number of shares Grossman may be deemed to beneficially own constitutes approximately 5.8% of the ordinary shares outstanding.

 

(c)Number of shares as to which such person has:

 

(i)sole power to vote or to direct the vote: 0

 

(ii)shared power to vote or to direct the vote: 54,658,680

 

(iii)sole power to dispose or to direct the disposition of: 0

 

(iv)shared power to dispose or to direct the disposition of: 54,658,680

 

Item 5Ownership of Five Percent or Less of a Class
  
 If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

 

Item 6Ownership of More than Five Percent on Behalf of Another Person
  
 Not Applicable

 

Item 7Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company
  
 See Item 2 above

 

 

 

 

CUSIP NO. 00653A107 13G Page 9 of 10 Pages

 

Item 8Identification and Classification of Members of the Group
  
 Not Applicable

 

Item 9Notice of Dissolution of Group
  
 Not Applicable

 

Item 10Certification
  
 By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

 

CUSIP NO. 00653A107 13G Page 10 of 10 Pages

 

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

 

Dated this 9th day of May, 2022.

 

PFM Health Sciences, LP   PFM Health Sciences GP, LLC
     
By: PFM Health Sciences GP, LLC,   By: /s/ Darin Sadow
  its general partner     Darin Sadow, Authorized Signatory
     
By: /s/ Darin Sadow    
  Darin Sadow, Authorized Signatory    
     
PARTNER Asset MANAGEMENT, LLC   BRIAN D. GROSSMAN
     
By: PFM Health Sciences GP, LLC,   By: /s/ Darin Sadow
  its manager     Darin Sadow, attorney-in-fact*
     
By: /s/ Darin Sadow    
  Darin Sadow, Authorized Signatory    

 

 

 

*Darin Sadow is signing on behalf of Brian Grossman as attorney-in-fact pursuant to a power of attorney dated August 4, 2011, and incorporated by reference herein. The power of attorney was filed as an attachment to a filing by certain of the Reporting Persons on Schedule 13G for K-V Pharmaceutical Company on August 5, 2011.